​

GeneDx (WGS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

WGS Stock Forecast

GeneDx (WGS) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $157.50, with a high of $170.00 and a low of $130.00. This represents a 104.94% increase from the last price of $76.85.

- $40 $80 $120 $160 $200 High: $170 Avg: $157.5 Low: $130 Last Closed Price: $76.85

WGS Stock Rating

GeneDx stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (90.91%), 1 Hold (9.09%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 1 10 Strong Sell Sell Hold Buy Strong Buy

WGS Price Target Upside V Benchmarks

TypeNameUpside
StockGeneDx104.94%
SectorHealthcare Stocks 15.45%
IndustryHealthcare Information Services Stocks 52.17%

Price Target Trends

1M3M12M
# Anlaysts3511
Avg Price Target$150.00$155.00$158.64
Last Closing Price$76.85$76.85$76.85
Upside/Downside95.19%101.69%106.43%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 2618---9
Feb, 26171--9
Jan, 26171--9
Dec, 25171--9
Nov, 25171--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 24, 2026Mark MassaroBTIG$170.00$87.0895.22%121.21%
Feb 24, 2026David WestenbergPiper Sandler$130.00$87.0849.29%69.16%
Feb 23, 2026Jefferies$150.00$87.0872.26%95.19%
Dec 22, 2025Canaccord Genuity$170.00$140.4421.05%121.21%
Dec 15, 2025Wells Fargo$155.00$151.372.40%101.69%
Dec 12, 2025BTIG$200.00$155.3628.73%160.25%
Oct 29, 2025BTIG$165.00$137.4020.09%114.70%
Oct 29, 2025Canaccord Genuity$160.00$137.4716.39%108.20%
Oct 29, 2025Guggenheim$170.00$137.4723.66%121.21%
Oct 20, 2025Canaccord Genuity$155.00$120.9428.16%101.69%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 24, 2026BTIGBuyBuyhold
Feb 24, 2026Piper SandlerOverweightOverweighthold
Feb 09, 2026Wells FargoEqual-WeightOverweightupgrade
Dec 12, 2025BTIGBuyBuyhold
Oct 29, 2025BTIGBuyBuyhold
Oct 29, 2025GuggenheimBuyBuyhold
Sep 11, 2025Piper SandlerOverweightOverweighthold
Aug 04, 2025Piper SandlerOverweightOverweighthold
Jun 30, 2025GuggenheimBuyBuyhold
May 15, 2025GuggenheimBuyinitialise

Financial Forecast

EPS Forecast

$-75 $-59 $-43 $-27 $-11 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-74.93$-53.63$-7.23$-1.94$-0.73--
Avg Forecast$-34.54$-29.04$-5.35$-0.27$0.55$1.46$2.68
High Forecast$-34.00$-28.74$-5.26$-0.26$0.56$2.17$2.75
Low Forecast$-35.31$-29.45$-5.49$-0.27$0.54$0.74$2.63
Surprise %116.94%84.68%35.14%618.52%-232.73%--

Revenue Forecast

$150M $220M $290M $360M $430M $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$212.19M$234.69M$202.57M$305.45M$427.54M--
Avg Forecast$203.77M$244.28M$192.76M$290.22M$338.77M$398.42M$476.30M
High Forecast$207.25M$246.90M$196.45M$295.78M$345.27M$406.06M$485.43M
Low Forecast$201.34M$242.35M$190.23M$286.41M$334.33M$393.20M$470.05M
Surprise %4.14%-3.92%5.09%5.25%26.20%--

Net Income Forecast

$-900M $-700M $-500M $-300M $-100M $100M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-245.39M$-548.98M$-175.77M$-52.29M$-21.02M--
Avg Forecast$-839.74M$-706.04M$-130.66M$-6.47M$13.36M$35.41M$65.16M
High Forecast$-826.71M$-698.78M$-127.93M$-6.33M$13.64M$52.75M$66.78M
Low Forecast$-858.41M$-715.90M$-133.39M$-6.60M$13.08M$18.08M$64.05M
Surprise %-70.78%-22.25%34.52%708.38%-257.31%--

WGS Forecast FAQ

Is GeneDx stock a buy?

GeneDx stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that GeneDx is a favorable investment for most analysts.

What is GeneDx's price target?

GeneDx's price target, set by 11 Wall Street analysts, averages $157.5 over the next 12 months. The price target range spans from $130 at the low end to $170 at the high end, suggesting a potential 104.94% change from the previous closing price of $76.85.

How does GeneDx stock forecast compare to its benchmarks?

GeneDx's stock forecast shows a 104.94% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the healthcare information services stocks industry (52.17%).

What is the breakdown of analyst ratings for GeneDx over the past three months?

  • March 2026: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 11.11% Strong Buy, 77.78% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 11.11% Strong Buy, 77.78% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.

What is GeneDx’s EPS forecast?

GeneDx's average annual EPS forecast for its fiscal year ending in December 2026 is $1.46, marking a -300.00% decrease from the reported $-0.73 in 2025. Estimates for the following years are.

What is GeneDx’s revenue forecast?

GeneDx's average annual revenue forecast for its fiscal year ending in December 2026 is $398.42M, reflecting a -6.81% decrease from the reported $427.54M in 2025. The forecast for.

What is GeneDx’s net income forecast?

GeneDx's net income forecast for the fiscal year ending in December 2026 stands at $35.41M, representing a -268.47% decrease from the reported $-21.021M in 2025. Projections indicate .